Future
There is a huge demand worldwide for research and development of new medicines, different than antibiotics, which do not allow the resistance by pathogens to be built up, specifically for treating sepsis, nosocomial infections, opportunistic infections and fungal infections.
Tesla BioScience progress path is the toward development of new medicine therapies that address these and other infectious diseases caused by:
- Methicillin-resistant Staphylococcus aureus (MRSA)
- Streptococcus faecalis
- Escherichia coli 0157H
- Salmonella typhimurium
- Mycobacterium tuberculosis
- Brucella spp.
- Shigella spp.
- Coxiella burnetii
- Vibrio cholerae
- Rickettsia prowazekii
- Klebsiella pneumoniae
- Myroides odoratimimus
- Acinetobacter baumannii complex – Pseudomonas aeruginosa